NCT04630964View on ClinicalTrials.gov

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

April 19, 2023

Study Completion Date

April 18, 2024

Conditions
Major Depressive DisorderDepression
Interventions
DRUG

Psilocybin

psilocybin 25 mg Single Oral Dose

DRUG

Niacin

niacin 100mg Single Oral Dose

Trial Locations (1)

Unknown

Northern Stockholm Spychiatry Clinic, Stockholm

All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

lead

Section for Affective Disorders; Northern Stockholm Psychiatry

OTHER

NCT04630964 - The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density | Biotech Hunter | Biotech Hunter